ADIM
ORMP icon

Alpha DNA Investment Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Alpha DNA Investment Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-386
Closed -$3K – 473
2021
Q1 		$3K Buy
+386
New +$3.17K ﹤0.01% 498

Other funds holding ORMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return

Alpha DNA Investment Management's ORMP Position: Q2 2021 in Review

Alpha DNA Investment Management sold out of Oramed Pharmaceuticals (ORMP) in Q2 2021, closing a stake of 386 shares — an estimated $3K sold.

Alpha DNA Investment Management first reported a position in ORMP in Q1 2021 and held it in 1 quarter. The position peaked at $3K in Q1 2021. 75 funds tracked by Wall St. Rank hold ORMP as of Q2 2021.

  • Alpha DNA Investment Management reported no remaining Oramed Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Alpha DNA Investment Management sold 386 Oramed Pharmaceuticals shares in Q2 2021, an estimated $3K.
  • Alpha DNA Investment Management first reported a position in Oramed Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Alpha DNA Investment Management's Oramed Pharmaceuticals position peaked at $3K in Q1 2021.
  • 75 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2021.

Based on Alpha DNA Investment Management's 13F filing for Q2 2021, filed 10 Aug 2021.